Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David P. Hochman | Founder, Chairman of the Board of Directors & CEO | 942k | -- | 1975 |
| Mr. Darren R. Sherman | Founder, President, COO & Director | 787k | -- | 1971 |
| Mr. Andrew Lawrence Taylor M.B.A. | Chief Financial Officer | 500.02k | -- | 1971 |
Orchestra BioMed Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 70
Description
Orchestra BioMed Holdings, Inc. operates as a biomedical company. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. The company's products also comprise FreeHold devices and additional minimally invasive surgery enabling devices. The company has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Corporate Governance
Upcoming Events
March 31, 2025 at 8:21 PM UTC
Orchestra BioMed Holdings, Inc. Earnings Date